ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0660

Performance of Creatinine-Based and Cystatin C-Based GFR Estimates in Pediatric Hematology-Oncology Patients

Session Information

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology

Authors

  • Benning, Tyler, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Ferdjallah, Asmaa, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Dinnes, Laura M, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Larson, Timothy S., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Titan, Silvia, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Hanna, Christian, Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background

Pediatric hematology-oncology (PHO) patients (pts) are at risk for kidney dysfunction from nephrotoxic exposures. Accurate GFR estimation (eGFR) is essential for diagnosis, drug dosing, and prognosis. While adult studies support combined creatinine-cystatin C equations as the most accurate, data in children are limited. We evaluated the performance of creatinine- and cystatin C-based equations against measured GFR (mGFR) in PHO pts.

Methods

Of 1301 PHO pts evaluated from Jan 2004 to May 2024, 26 met inclusion criteria: mGFR via iothalamate (n=24) or iohexol (n=2) with standardized serum creatinine and cystatin C measured within 5 days. For pts with multiple mGFRs, only the earliest was used. We excluded cases involving kidney transplant and amputation, and limited analysis to mGFR ≤150 mL/min/1.73 m2. eGFRs were calculated using the CKiD under age 25 (CKiD U25; validated ≥1 year) and European Kidney Function Consortium (EKFC; validated ≥2 years) equations. eGFRs were compared to mGFR using correlation, P10/P30 accuracy, median bias, and RMSE. Confidence intervals used Fisher transformation and binomial exact methods.

Results

Median age was 10.3 years; 54% were male; and 85% were white. Diagnoses included solid, hematologic, and neuro-oncologic malignancies, as well as benign hematologic conditions. Most (62%) underwent hematopoietic stem cell transplantation. eGFR performance metrics are shown in Table 1. Differences were modest with overlapping confidence intervals. Among all pts, CKiD U25Avg showed slightly better performance than other CKiD equations. Among patients ≥2 years old, CKiD U25Avg and EKFCcr outperformed cystatin C-only equations.

Conclusion

In a diverse PHO cohort, the CKiD U25Avg and EKFCcr methods showed slightly better accuracy in predicting mGFR compared to others. Cystatin C-only equations were more biased and less accurate. Findings support using modern creatinine-based or combined equations for eGFR in PHO pts, though further studies are needed.

Digital Object Identifier (DOI)